Steroid News and Research

RSS

Evaluating the use of megadoses of corticosteroids as a treatment of COVID-19

In a new study, researchers have been investigating the effects of megadoses of corticosteroids on hospitalized COVID-19 patients.

26 Jan 2022

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

In a new study, a team of researchers investigated the impact of the fourth dose of a vaccine against COVID-19 in kidney transplant recipients, who had not mounted a humoral immune response to three doses of vaccine.

11 Jan 2022

Drugs that block mineralocorticoid receptor may help protect bone cells during aging

Drugs we take like prednisone can weaken our bones and so can aging, and scientists working to prevent both have some of the first evidence that the best target may not be the logical one.

5 Jan 2022

Measuring airway inflammation when diagnosing and treating asthma patients

In this interview, Carol Stonham, the head of a Locality Based FeNO referral service, talks to NewsMed about measuring airway inflammation when diagnosing and treating asthma patients.

From Bedfont® Scientific Ltd 21 Dec 2021

Humanized mice reveals why few COVID-19 cases are more severe than others

Why do 80 to 90% of people infected with COVID-19 experience only mild cases while 10 to 20% face more severe or life-threatening symptoms?

20 Dec 2021

A nematode infection can become severe and deadly with the use of corticosteroids

Healthcare workers in tropical and sub-tropical settings where strongyloidiasis is prevalent or caring for patients who have travelled to such areas, need to maintain a high level of awareness about the use of corticosteroids, including when this class of anti-inflammatories is given to patients suspected of infection with SARS-CoV-2.

19 Dec 2021

Persistence of symptoms up to a year after hospitalization for COVID-19

Researchers conducted a prospective cohort study to determine the persisting COVID-19 associated symptoms after hospitalization and their risk factors.

15 Dec 2021

Thrombosis may increase mortality risk in hospitalized COVID-19 patients

A team of US-based scientists has recently explored various risk factors associated with the poor prognosis of coronavirus disease 2019 (COVID-19). They have identified thrombosis-related risk factors as a major predictor of in-hospital COVID-19 related mortality. The study is currently available on the medRxiv* preprint server while awaiting peer review.

14 Dec 2021

UTSW study points to a new way to fight parasitic nematode diseases

Combining two agents to block a parasitic worm's life cycle boosted survival from a potentially deadly tropical disease to 85% in animal models, far better than either treatment alone, according to a proof-of-concept study led by UT Southwestern Medical Center pharmacologists.

11 Dec 2021

Chemicals from certain personal care products may impact maternal hormone levels during pregnancy

Use of certain personal care products during pregnancy may impact maternal hormone levels, according to a new Rutgers study.

11 Dec 2021

Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.

9 Dec 2021

A case of post-vaccination MIS in an adult without prior SARS-CoV-2 infection

A new case study on the report of multisystem inflammatory syndrome (MISC) in a 22-year-old woman in South Korea after vaccination.

5 Dec 2021

Risk of COVID-19 hospitalization among children with markers of uncontrolled asthma

The paper describes a national cohort study including all children in Scotland between the ages of 5 and 17 years who were part of the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II).

3 Dec 2021

People with allergic conditions may have a lower risk of COVID-19 infection, finds study

People with allergic conditions such as hay fever, rhinitis, and atopic eczema, may have a lower risk of COVID-19 infection, especially if they also have asthma, finds a large, population-based study of UK adults, published online in the respiratory journal Thorax.

1 Dec 2021

For older adults, smelling the roses may be more difficult

The reports from covid-19 patients are disconcerting. Only a few hours before, they were enjoying a cup of pungent coffee or the fragrance of flowers in a garden. Then, as if a switch had been flipped, those smells disappeared.

1 Dec 2021

Can dexamethasone reduce prolonged COVID-19 symptoms?

A new study assesses hospitalized patients after recovering from COVID-19 by comparing the individuals before and after being treated with dexamethasone.

24 Nov 2021

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

A recent study evaluates the immune responses elicited by COVID-19 vaccines in infliximab- or vedolizumab-treated IBD patients.

15 Nov 2021

Study: Patients meeting a particular criteria need invasive procedures to treat chronic neck pain

The use of radiofrequency ablation--targeted heat from an electrical current to ease nerve pain--may be helpful for treating chronic neck pain, but only in patients meeting particular criteria, conclude evidence-based consensus guidelines, published online in the journal Regional Anesthesia & Pain Medicine.

12 Nov 2021

Results of high-impact clinical trials could affect kidney-related medical care

The results of numerous high-impact clinical trials that could affect kidney-related medical care will be presented online at ASN Kidney Week 2021 November 4–November 7.

7 Nov 2021

Study: Ultra-low rituximab dose maintains low disease activity for most RA patients

New research presented this week at ACR Convergence, the American College of Rheumatology's annual meeting, shows that in one study, the majority of rheumatoid arthritis patients on an ultra-low dose of the drug rituximab maintained low disease activity for up to four years, and rarely needed to switch to other biologic drugs or glucocorticoids to control their disease.

2 Nov 2021